Sevelabind-800 Tablet 10's is a medication classified as a phosphate binder, specifically designed to address elevated phosphate levels in the body, a condition known as hyperphosphataemia. It is primarily utilized in adult patients undergoing dialysis as a consequence of severe kidney disease, including those receiving hemodialysis or afflicted with chronic kidney disease. Containing sevelamer as its active ingredient, Sevelabind-800 Tablet 10's functions by binding with phosphate in the gastrointestinal tract to diminish its absorption. By effectively reducing excess phosphate levels in the bloodstream, this medicine helps prevent the hazardous accumulation of phosphate, supports bone health, and lowers the risk of cardiovascular issues like heart disease and strokes.

To achieve optimal outcomes, it is crucial to adhere strictly to the prescribed dosage and schedule recommended by your healthcare provider when taking Sevelabind-800 Tablet 10's. While generally well-tolerated, some individuals may experience side effects such as vomiting, upper abdominal pain, nausea, diarrhea, stomach ache, indigestion, and flatulence. Should these side effects persist or worsen, it is advisable to consult your doctor promptly for further guidance on managing them effectively.

When considering the suitability of Sevelabind-800 Tablet 10's, certain precautions should be observed. Individuals with known allergies to any constituents of the medication, low blood phosphate levels, or bowel obstruction should avoid its use. Furthermore, caution is advised for individuals encountering difficulties with swallowing, stomach and bowel motility issues, recent major stomach or bowel surgery, or severe inflammatory bowel disease. Pregnant and breastfeeding women are advised to seek medical advice before initiating treatment with Sevelabind-800 Tablet 10's to ensure safety for both mother and child.

In contrast, Sevelabind 400 Tablet containing Sevelamer is prescribed to regulate serum phosphorous levels in patients with long-standing kidney issues necessitating dialysis. High serum phosphorous levels commonly result from renal failure, which diminishes the filtration of inorganic phosphate, leading to its escalation in the bloodstream. During the course of treatment, periodic tests may be advised by your healthcare provider to monitor and mitigate potential side effects. Dietary compliance as instructed by the doctor plays a significant role in ensuring treatment effectiveness.

Patients with abnormally low blood phosphorus levels or bowel obstructions are not suitable candidates for SEVELABIND 400 TABLET. Additionally, cautious administration is recommended for individuals grappling with swallowing difficulties, stomach and bowel motility complications, or those with a history of major bowel surgery. Pregnant women should only use Sevelabind-400 Tablet if deemed essential by their healthcare provider, while breastfeeding women must consult their doctor before commencing treatment due to potential effects on nursing infants.

Overall, both Sevelabind-800 Tablet 10's and Sevelabind 400 Tablet are valuable pharmaceutical options in managing phosphate levels in patients with kidney-related conditions, albeit with considerations for individual health circumstances and potential side effects.